ZVRA
Zevra Therapeutics Inc (ZVRA)
Healthcare • NASDAQ • $11.13+1.18%
- Symbol
- ZVRA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $11.13
- Daily Change
- +1.18%
- Market Cap
- $657.95M
- Trailing P/E
- 5.54
- Forward P/E
- 6.56
- 52W High
- $13.16
- 52W Low
- $7.16
- Analyst Target
- $23.00
- Dividend Yield
- N/A
- Beta
- 0.88
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYF…
Company websiteResearch ZVRA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.